MX2011011526A - Formulacion lipida de promotor de apoptosis. - Google Patents

Formulacion lipida de promotor de apoptosis.

Info

Publication number
MX2011011526A
MX2011011526A MX2011011526A MX2011011526A MX2011011526A MX 2011011526 A MX2011011526 A MX 2011011526A MX 2011011526 A MX2011011526 A MX 2011011526A MX 2011011526 A MX2011011526 A MX 2011011526A MX 2011011526 A MX2011011526 A MX 2011011526A
Authority
MX
Mexico
Prior art keywords
lipid formulation
apoptosis promoter
bcl
abt
phospholipid
Prior art date
Application number
MX2011011526A
Other languages
English (en)
Inventor
Paul David
Anthony R Haight
Michael Fickes
Cristina Fischer
Katherine Heemstra
Kennan Marsh
Vitaly Rubin
Peter Mayer
Yeshwant Sanzgiri
Eric Schmitt
Ping Tong
Deliang Zhou
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2011011526A publication Critical patent/MX2011011526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica que se puede suministrar por vía oral comprende un sistema portador de fármaco que tiene un compuesto inhibidor de proteína de la familia de Bcl-2, por ejemplo, ABT-263, en solución en un vehículo sustancialmente no acuoso que comprende por lo menos un fosfolípido y un agente de solubilización farmacéuticamente aceptable. La composición es apropiada para administración oral a un individuo en necesidad de lo mismo para tratamiento de una enfermedad caracterizada por sobre-expresión de una o más proteínas anti-apoptóticas de la familia de Bcl-2, por ejemplo cáncer.
MX2011011526A 2009-04-30 2010-04-30 Formulacion lipida de promotor de apoptosis. MX2011011526A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17424509P 2009-04-30 2009-04-30
PCT/US2010/033074 WO2010127192A1 (en) 2009-04-30 2010-04-30 Lipid formulation of apoptosis promoter

Publications (1)

Publication Number Publication Date
MX2011011526A true MX2011011526A (es) 2011-11-18

Family

ID=42732500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011526A MX2011011526A (es) 2009-04-30 2010-04-30 Formulacion lipida de promotor de apoptosis.

Country Status (17)

Country Link
US (1) US20100280031A1 (es)
EP (1) EP2424500A1 (es)
JP (1) JP2012525434A (es)
KR (1) KR20120013416A (es)
CN (1) CN102458361A (es)
AR (1) AR076512A1 (es)
AU (1) AU2010242925A1 (es)
BR (1) BRPI1014368A2 (es)
CA (1) CA2758534A1 (es)
IL (1) IL215473A0 (es)
MX (1) MX2011011526A (es)
RU (1) RU2011148518A (es)
SG (1) SG175147A1 (es)
TW (1) TW201043605A (es)
UY (1) UY32600A (es)
WO (1) WO2010127192A1 (es)
ZA (1) ZA201107593B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP3238709B1 (en) * 2011-04-28 2020-07-01 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
CN102836160A (zh) * 2012-10-10 2012-12-26 武汉大学 一种治疗癌症的组合药物
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
JP2022553820A (ja) 2019-11-05 2022-12-26 アッヴィ・インコーポレイテッド 骨髄線維症及びｍｐｎ関連障害をナビトクラクスで処置する際に使用するための投与レジメン

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
PL364910A1 (en) * 2001-01-31 2004-12-27 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
KR101509440B1 (ko) * 2005-05-12 2015-04-07 애브비 바하마스 리미티드 아폽토시스 촉진제
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
MX2010003642A (es) * 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
CA2708223A1 (en) * 2007-12-06 2009-06-11 Andrew Krivoshik Oral compositions of abt-263 for treating cancer
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
BRPI1014027A2 (pt) * 2009-06-18 2019-09-24 Abbott Lab suspensão de fármaco de nanopartícula estável.
WO2011034934A1 (en) * 2009-09-20 2011-03-24 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases

Also Published As

Publication number Publication date
AR076512A1 (es) 2011-06-15
RU2011148518A (ru) 2013-06-10
CN102458361A (zh) 2012-05-16
IL215473A0 (en) 2011-12-29
EP2424500A1 (en) 2012-03-07
BRPI1014368A2 (pt) 2016-04-05
TW201043605A (en) 2010-12-16
CA2758534A1 (en) 2010-11-04
JP2012525434A (ja) 2012-10-22
UY32600A (es) 2010-12-31
SG175147A1 (en) 2011-11-28
KR20120013416A (ko) 2012-02-14
AU2010242925A1 (en) 2011-11-10
WO2010127192A1 (en) 2010-11-04
ZA201107593B (en) 2012-06-27
US20100280031A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
NZ596047A (en) Stabilized lipid formulation of apoptosis promoter
ES2745471T3 (es) Formulaciones orales de liberación inmediata para quinazolinonas sustituidas
UY32599A (es) Formulación oral sólida de abt-263
MX2011011526A (es) Formulacion lipida de promotor de apoptosis.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
AU2008347158A8 (en) Oral pharmaceutical dosage forms
MX356411B (es) Derivados del tipo del azaindazol o diazaindazol como medicamento.
MX2011011511A (es) Sal de abt-263 y fomas en estado solido de la misma.
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
MX2012007325A (es) Capsula de abt-263.
UA102885C2 (ru) Таблетка для орального введения, которая содержит тамсулозин и солифенацин
TN2012000046A1 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorfers
CN113164420A (zh) 治疗组合物
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
UA109879C2 (uk) Похідні нітрилу, їх застосування у фармацевтичних цілях і в композиції
MX2013001637A (es) Composiciones farmaceuticas de liberacion controlada oral de blonanserina.
MX2010003112A (es) Formas de dosificacion solubles que contienen derivados de cephem adecuados para administracion parenteral.
UA115250C2 (uk) Фармацевтичні комбінації
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
ATE546133T1 (de) Orale dosierform mit trisubstituierten glycerin- verbindungen
UA107351C2 (en) Stabilized lipid formulation of apoptosis promoter
WO2011035343A3 (en) Phentermine liquid dosage form

Legal Events

Date Code Title Description
FA Abandonment or withdrawal